LINCOLNSHIRE, ILLINOIS--(Marketwire - April 10, 2008) - MonoGen, Inc. (TSX: MOG) today announced that it has received a letter from the FDA indicating that two of the six responses to observations received during the previously announced inspection of its facilities were not adequate and that a follow up inspection would be required. This letter stems from MonoGen’s 180-day PMA Supplement filed with the FDA in October 2007.
